Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 08 2025
0mins
Source: Benzinga
ZyVersa Therapeutics Updates: ZyVersa Therapeutics' stock (ZVSA) surged 56% following the FDA's Emergency Compassionate Use authorization for their cholesterol efflux mediator VAR 200, aimed at treating ApoCII amyloidosis and currently in Phase 2 trials for diabetic kidney disease.
Clinical Development Insights: The company is focusing on VAR 200's potential to improve kidney health by removing excess lipids, with plans to expand indications to orphan kidney diseases like focal segmental glomerulosclerosis (FSGS) and Alport syndrome.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
